Wetherby Asset Management Inc. decreased its position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 0.2% during the second quarter, Holdings Channel reports. The firm owned 5,299 shares of the medical equipment provider’s stock after selling 8 shares during the period. Wetherby Asset Management Inc.’s holdings in Zimmer Biomet Holdings were worth $680,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Trent Capital Management Inc. NC purchased a new position in Zimmer Biomet Holdings during the second quarter worth approximately $5,266,000. Canada Pension Plan Investment Board boosted its position in Zimmer Biomet Holdings by 7.7% in the second quarter. Canada Pension Plan Investment Board now owns 51,861 shares of the medical equipment provider’s stock worth $6,659,000 after buying an additional 3,700 shares during the period. Pointe Capital Management LLC boosted its position in Zimmer Biomet Holdings by 39.3% in the second quarter. Pointe Capital Management LLC now owns 3,866 shares of the medical equipment provider’s stock worth $496,000 after buying an additional 1,090 shares during the period. Trexquant Investment LP purchased a new position in Zimmer Biomet Holdings during the second quarter worth approximately $231,000. Finally, Global X Management Co. LLC boosted its position in Zimmer Biomet Holdings by 41.6% in the second quarter. Global X Management Co. LLC now owns 6,315 shares of the medical equipment provider’s stock worth $811,000 after buying an additional 1,854 shares during the period. Institutional investors own 83.62% of the company’s stock.

Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) opened at 111.70 on Friday. Zimmer Biomet Holdings, Inc. has a 1-year low of $95.63 and a 1-year high of $133.49. The firm has a market capitalization of $22.59 billion, a PE ratio of 31.81 and a beta of 1.20. The firm has a 50-day moving average price of $124.93 and a 200-day moving average price of $121.26.

Zimmer Biomet Holdings (NYSE:ZBH) last released its earnings results on Thursday, July 27th. The medical equipment provider reported $2.08 earnings per share for the quarter, missing the Zacks’ consensus estimate of $2.10 by $0.02. The firm had revenue of $1.95 billion during the quarter, compared to the consensus estimate of $1.95 billion. Zimmer Biomet Holdings had a return on equity of 16.70% and a net margin of 9.12%. The business’s quarterly revenue was up 1.1% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $2.02 EPS. On average, analysts forecast that Zimmer Biomet Holdings, Inc. will post $8.24 EPS for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Friday, October 27th. Investors of record on Friday, September 22nd will be given a $0.24 dividend. The ex-dividend date of this dividend is Thursday, September 21st. This represents a $0.96 dividend on an annualized basis and a yield of 0.86%. Zimmer Biomet Holdings’s payout ratio is 27.59%.

TRADEMARK VIOLATION NOTICE: This piece of content was first posted by Watch List News and is the sole property of of Watch List News. If you are reading this piece of content on another domain, it was illegally stolen and reposted in violation of international copyright and trademark laws. The original version of this piece of content can be read at https://www.watchlistnews.com/wetherby-asset-management-inc-reduces-stake-in-zimmer-biomet-holdings-inc-nysezbh/1477433.html.

A number of research firms have commented on ZBH. Zacks Investment Research cut Zimmer Biomet Holdings from a “hold” rating to a “strong sell” rating in a research note on Tuesday. BidaskClub cut Zimmer Biomet Holdings from a “hold” rating to a “sell” rating in a research note on Tuesday, August 1st. BMO Capital Markets upped their price target on Zimmer Biomet Holdings from $136.00 to $140.00 and gave the stock an “outperform” rating in a research note on Friday, July 28th. Leerink Swann upped their price target on Zimmer Biomet Holdings from $141.00 to $146.00 and gave the stock an “outperform” rating in a research note on Friday, July 28th. Finally, Oppenheimer Holdings, Inc. set a $137.00 price target on Zimmer Biomet Holdings and gave the stock a “buy” rating in a research note on Friday, July 28th. Four equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the company. The stock has a consensus rating of “Hold” and a consensus price target of $136.90.

In related news, insider Sang Yi sold 17,731 shares of the business’s stock in a transaction that occurred on Monday, June 12th. The stock was sold at an average price of $124.56, for a total value of $2,208,573.36. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP Tony W. Collins sold 16,986 shares of the business’s stock in a transaction that occurred on Monday, July 31st. The stock was sold at an average price of $121.74, for a total value of $2,067,875.64. The disclosure for this sale can be found here. Insiders own 1.07% of the company’s stock.

Zimmer Biomet Holdings Company Profile

Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.

Want to see what other hedge funds are holding ZBH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zimmer Biomet Holdings, Inc. (NYSE:ZBH).

Institutional Ownership by Quarter for Zimmer Biomet Holdings (NYSE:ZBH)

Receive News & Ratings for Zimmer Biomet Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet Holdings Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.